Advertisement

Generex Biotechnology Corp., a Worcester drug delivery-focused firm, is taking in at least $3 million in an investor offering that combines common stock and warrants to purchase common stock. The news comes as the company and its immunotherapeutics subsidiary Antigen Express Inc. plan to increase enrollment in a Phase 2 clinical study of a breast cancer vaccine.

Generex officials said the investment would help fund research and development, preclinical and clinical trials, new drug application filings and general working capital.

SOURCE

Advertisement
Advertisement